Globus Medical Inc. Class A (GMED) Stock Price, News, Analysis

Technical Score (1D)

BUY

News Sentiment

BULLISH

Globus Medical’s latest earnings report revealed a notable improvement in adjusted EBITDA margins, indicating stronger earnings power than previously expected. The margin expansion suggests the company has successfully managed cost structures and achieved higher profitability per procedure. However, the company’s guidance also highlighted ongoing hospital and payer pricing pressures that could curb further upside in the near term. This duality means investors face a valuation uncertainty: the stock appears undervalued on broad metrics, yet pricing headwinds may temper the upside potential. Over the next 1–10 trading days, the market will likely focus on how the company balances margin gains against the risk of reimbursement cuts. Watch for any updates to future earnings guidance, as a more optimistic outlook could lift sentiment. Also monitor any new payer negotiations or regulatory changes that could impact reimbursement rates. If the company can secure higher payer rates or demonstrate resilience to pricing pressure, it could justify a higher valuation multiple. Conversely, a failure to mitigate pricing risks could keep the stock trading at a discount relative to its fundamentals.

GMED|Company Info

No Data Available

Sector

Industry

Exchange

Country

Website

Symbol

GMED

Description

No description available for this symbol yet.

GMED|Earnings Snapshot

EPS

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$1.19	-	-
Q3'25	$0.78	$1.18	+51.1%

Revenue

EstBeatMiss

Qtr	Est	Actual	+/−
Q3'26	$808M	-	-
Q3'25	-	$769M	-

Full Earnings BreakdownEstimates, actuals, guidance, and historical context

→

Market Data

GMED Stock Snapshot

GMED is currently trading at $83.29, giving Globus Medical Inc. Class A a market cap of 11.54B and a P/E ratio of 21.6. Today's range spans $83.19–$84.50, with shares opening at $83.99 and moving down $0.79 (0.9%) from the prior close. DailyIQ's technical score sits at 95/100 (BUY) with a news sentiment reading of 77/100.

Over the past year GMED has traded between $54.15 and $101.40 - the current price is +53.8% off the 52-week low and -17.9% from the high. 25 analysts cover the stock with a Buy consensus and a mean 12-month target of $103.23 (range $84.00–$125.00), implying upside of +23.9%.

The combination of bullish technicals and bullish sentiment for Globus Medical Inc. Class A (GMED) is the kind of setup that shows up in systematic screens before the more discretionary investors arrive. Score 95/100 (BUY), price $83.29 (in the middle of its 52-week range), sentiment 77/100. The current P/E ratio stands at 21.6. At 11.54B in the broader market market cap, this large-cap name has the right size to matter to a wide range of buyers. Annual range: $54.15–$101.40.

Earnings revision cycles in large-cap the broader market names tend to compound: when technicals confirm a BUY thesis (95/100) and news sentiment (77/100, bullish) supports the narrative, analyst upgrades follow price rather than lead it. At $83.29 (in the middle of its 52-week range), GMED's position within the $54.15–$101.40 annual range suggests there's room for multiple expansion before the stock encounters meaningful technical resistance.

News Sentiment Analysis

Sentiment gathered from recent headlines

77/100

Strong NegativeNeutralStrong Positive

BULLISH

Recent News Coverage

Most recent articles, ranked by recency (click to expand).

5 articles

What did this article say?

Globus Medical (GMED) meets the Decent Value criteria, boasting solid valuation, robust profitability, a healthy balance sheet, and consistent growth, positioning it as a defensible long‑term investment.

What did this article say?

Globus Medical’s recent earnings highlighted stronger adjusted EBITDA margins, suggesting improved earnings power. However, hospital and payer pricing pressures could temper upside, leaving room for valuation uncertainty. The company appears undervalued on broad valuation checks, yet investors must weigh margin gains against pricing risks. Monitoring future earnings guidance and payer negotiations will clarify the stock’s true value.

What did this article say?

An insider sold shares worth $2,175,965, indicating potential short-term negative sentiment. The sale could reflect personal liquidity needs or a bearish view on the company’s near-term prospects. Investors should monitor subsequent insider activity and any accompanying statements for context. The transaction does not necessarily signal a broader market shift but warrants caution.

What did this article say?

Globus Medical’s shares fell 8.5% as analysts project a slowdown in second‑half growth. Free‑cash‑flow margins are expected to normalize, while the company’s recruiting and potential mergers and acquisitions are seen as key growth drivers. The dip in valuation is viewed as a buying opportunity rather than a signal of fundamental weakness.

What did this article say?

Globus Medical has been rated a buy with a target return of 17.5% over the next four quarters, based on a steady 10.56x EV/EBITDA multiple. The company has demonstrated consistent margin expansion across seven consecutive quarters, indicating robust operational performance. This valuation reflects confidence in continued profitability and a solid cost structure. Investors should watch upcoming earnings releases for confirmation of margin trends and any guidance updates on valuation multiples.

End of results